Locati LD, Cavalieri S, Bergamini C, et al. - In this phase 2 trial, researchers tested axitinib in a cohort of recurrent/metastatic salivary gland carcinomas (SGCs) including non-adenoid cystic carcinoma. Until progression or unacceptable toxicity, axitinib was administered at 10 mg daily (dose escalation allowed). If more than three out of 26 responses were observed, null hypothesis would be dismissed. In this analysis, 26 patients were treated. This trial did not fulfil its main endpoint and therefore axitinib should not be regarded in SGCs for further inquiries. Scientific literature was reflected in the demonstrated safety profile. The most frequent adverse events were stomatitis, fatigue and hypertension.